IBTA e-News October 2020 out now

By 29th October 2020 IBTA News
[28 October 2020] The IBTA's monthly e-News has been released and has emailed to all subscribers. To sign up to receive your copy, click here.

You can also read the IBTA e-News October 2020 edition in full online here.

Some of the highlights from this month's round-up:

  • The announcement that we are in International Brain Tumour Awareness Week, a celebration of awareness-raising activities in which the international brain tumour community unites to draw attention to the challenges of brain tumours and the need for an increased research effort.
  • The announcement and our warm congratulations to Matthias Preusser, Professor for internal oncology of MedUni Vienna and Head of the Clinical Division for oncology of MedUni Vienna at AKH Vienna, who has been elected President of the European Association of Neuro-Oncology (EANO) for 2020-2022.
  • News that a clinical trial of 5-ALA (5-Aminolevulinic Acid) – a drug designed to aid neurosurgery by causing brain tumour cells to fluoresce (glow) pink under blue light - for children and adolescents with ‘supratentorial’ brain tumours (those in the upper brain regions) is taking place in centres across Germany.
  • Results from the ongoing Australia-based ZERO Childhood Cancer National Clinical Trial have been published in Nature Medicine with encouraging signs: Of the first 250 children enrolled in the program, testing helped identify at least one new treatment that could help in 67 per cent (134) of those cases.
  • Key molecules that regulate a glioblastoma's ability to resist radiotherapy have been identified by researchers and represent a target for future therapies, according to a paper published in the journal Neuro-Oncology Advances.
  • Molecules that are a fusion of antibodies (proteins that latch on to specific targets) and cytokines (which regulate and stimulate the immune system) might serve as an effective treatment for glioblastoma, according to research published in the journal Science Translational Medicine.
  • ublished in Clinical Cancer Research, a team of researchers has developed a ‘liquid biopsy’ blood test that can reliably detect and monitor the genetic mutations present in the tiny amounts of DNA that escape from glioma brain tumours into the circulation (termed “cell-free DNA”).

Our monthly e-News highlights items of interest to our international brain tumour community and is emailed to approximately 6,000 recipients. It gives a round-up of the latest research and treatment developments, news about brain tumour patient organisations around the world, and key forthcoming neuro-oncology scientific and patient conferences. You can sign up to receive the e-News every month by registering here.

To see an archive of existing e-News issues, click here.

let us know you agree to cookies

The IBTA website uses cookies to give you the best online experience in accordance with our cookies policy. If you are happy, please confirm by clicking the 'Accept' button below.